Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.64 - $31.02
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.48M
Market Cap
$12.55B
Enterprise Value$13.14B
Total Cash (Recent Filing)kr9.86B
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)10.9
Beta0.60
Next Earnings
May 08, 2025EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding661,972,400
10 Day Avg. Volume2,035,259
30 Day Avg. Volume1,478,815
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)N/A
Price to Sales (P/S)4.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.67Price Target Upside81.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGenmab posted DKK 21.5B in FY24 total revenues, a 31% year-over-year increase, driven by Darzalex, Kesimpta, and Epkinly.
Pipeline And R&DGenmab's R&D engine has produced several blockbuster assets and significant royalty streams, providing funding for partnered and wholly owned assets.
Bears Say
Product DevelopmentJNJ announced the decision to not exercise its option for GEN3014, which was largely expected and considered unfortunate.
Product SafetyGEN3014 showed deeper responses than Darzalex Faspro but was associated with an inferior safety and tolerability profile.
---
Ownership Overview
―
Insiders
1.17% Mutual Funds
2.39% Other Institutional Investors
95.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $18.64 and its highest was $31.02 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $12.55B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 12, 2025. The company reported $0.844 earnings per share for the quarter, beating the consensus estimate of $0.374 by $0.47.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.22.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,972,400 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.844 in its last earnings report, beating expectations of $0.374. Following the earnings report the stock price went up 4.235%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
---
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.67 (81.90% Upside)
$34.67 (81.90% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 307.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.52%
12-Months-Change
Fundamentals
Return on Equity
23.16%
Trailing 12-Months
Asset Growth
21.65%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
---
GMAB Company Deck
---
GMAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with significant revenue and profit growth, driven by the success of commercialized medicines like EPKINLY and TIVDAK. The company has a robust pipeline with strategic investments and provided optimistic guidance for 2025. However, there are minor concerns about EPKINLY's flat sales in Q4 and the company's dependency on key products amid competitive pressures.Read More>---
GMAB Stock 12 Month Forecast
Average Price Target
$34.67
▲(81.90% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-16.47%
reiterated a buy rating 9 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -16.47% per trade.
---